![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Effect of Renal Impairment on Single-Dose
Pharmacokinetics of Daclatasvir, an HCV NS5A Inhibitor
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC, May 19-21, 2014
Garimella T,1 Wang R,1 Luo W-L,2 Hwang C,1 Sherman D,1 Kandoussi H,2 Marbury T,3 Alcorn H,4 Bertz R,1 Bifano M1
1Bristol-Myers Squibb Research and Development, Hopewell, NJ, USA; 2Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA;
3Orlando Clinical Research Center, Orlando, FL, USA; 4DaVita Clinical Research, Minneapolis, MN, USA
![Pharm1.gif](../images/052214/052214-3/Pharm1.gif)
![Pharm2.gif](../images/052214/052214-3/Pharm2.gif)
![Pharm3.gif](../images/052214/052214-3/Pharm3.gif)
![Pharm4.gif](../images/052214/052214-3/Pharm4.gif)
![Pharm5.gif](../images/052214/052214-3/Pharm5.gif)
![Pharm6.gif](../images/052214/052214-3/Pharm6.gif)
![Pharm7.gif](../images/052214/052214-3/Pharm7.gif)
![Pharm8.gif](../images/052214/052214-3/Pharm8.gif)
![Pharm9.gif](../images/052214/052214-3/Pharm9.gif)
![Pharm10.gif](../images/052214/052214-3/Pharm10.gif)
![Pharm11.gif](../images/052214/052214-3/Pharm11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|